Gene Therapy Market – United States

Market Statistics

Base Year: 2023

Historical Years: 2018-2023

Forecast Years: 2024-2032

Market Growth Rate: 12.2% (2024-2032)

The United States gene therapy market is rapidly expanding, driven by a combination of scientific advancements, regulatory support, and increasing demand for innovative treatments targeting previously incurable genetic disorders.  According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 12.2% from 2024 to 2032.

Download sample copy of the Report: https://www.imarcgroup.com/united-states-gene-therapy-market/requestsample

United States Gene Therapy Industry Trends and Drivers:

• Scientific Advancements:

• • Gene Editing Technologies:
    • Significant progress in gene editing technologies, particularly CRISPR-Cas9, has revolutionized the field by enabling precise and efficient modifications of genetic material.
    • This technology opens new avenues for treating a wide range of genetic disorders, including hemophilia, sickle cell anemia, and certain types of inherited blindness.
  • Viral Vector Delivery Systems:
    • Advancements in viral vector delivery systems, such as adeno-associated viruses (AAVs), have improved the safety and efficacy of gene therapies.
    • These systems reduce the risk of immune reactions and enhance the delivery of therapeutic genes to target cells.

• Regulatory Support:

• • FDA’s Supportive Framework:
    • The Food and Drug Administration (FDA) has implemented a more streamlined and supportive regulatory framework for gene therapies, recognizing their potential to address unmet medical needs.
    • Expedited pathways like Fast Track, Breakthrough Therapy, and Regenerative Medicine Advanced Therapy (RMAT) designations allow for faster approval processes and earlier patient access to promising treatments.
  • Landmark Approvals:
    • The approval of landmark gene therapies, such as Luxturna for inherited retinal dystrophy and Zolgensma for spinal muscular atrophy, has set important precedents and encouraged further investment in the market.

• Growing Demand for Innovative Treatments:

• • Prevalence of Genetic Disorders:
    • The growing prevalence of genetic disorders, coupled with increasing awareness and demand for personalized medicine, is fueling the gene therapy market.
    • Patients and healthcare providers are seeking more targeted and effective treatment options, especially for conditions with limited or no existing treatments.
  • Promise of Curative Outcomes:
    • The potential for curative outcomes with a single administration of gene therapy contrasts with the chronic nature of traditional treatments, further driving demand.

• Investment and Collaboration:

• • Strong Public and Private Sector Investment:
    • Significant funding for research and development from both public and private sectors is bolstering the market’s growth.
  • Pharmaceutical and Biotech Partnerships:
    • Pharmaceutical companies are increasingly partnering with biotech firms to accelerate the development and commercialization of gene therapies, driving the expansion of the U.S. gene therapy market.

• Market Growth Potential:

• • The convergence of these factors positions the U.S. gene therapy market for sustained growth, with the potential to transform the treatment landscape for a wide range of genetic diseases.

United States Gene Therapy Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest United States gene therapy market share. It includes forecasts for the period 2024-2032 and historical data from 2018-2023 for the following segments.

The report has segmented the market into the following categories:

Gene Type Insights:

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide Gene
• Deficiency
• Growth Factors
• Receptors
• Others

Vector Type Insights:

• Viral Vector
  • Adenoviruses
  • Lentiviruses
  • Retroviruses
  • Adeno-Associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • nia ViruVaccis
  • Others
• Non-Viral Techniques
  • Naked and Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

Delivery Method Insights:

• In-Vivo Gene Therapy
• Ex-Vivo Gene Therapy

Application Insights:

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Disease
• Others

Regional Insights:

• Northeast
• Midwest
• South
• West

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Request for customization:  https://www.imarcgroup.com/request?type=report&id=11240&flag=F

Key highlights of the Report:

• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:  

IMARC Group 

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145